netFormulary Bradford Teaching Hospitals NHS
NHS Foundation Trust Formulary  
 Formulary Chapter 2: Cardiovascular system - Full Chapter
Chapter Links...
02.03.02  Expand sub section  Drugs for arrhythmias
02.03.02  Expand sub section  Supraventricular arrhythmias
View adult BNF View SPC online View childrens BNF  Track Changes
Secondary care only 
Dronedarone (Multaq)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
  • Restricted for cardiologist initiation in accordance with NICE guidance (TA197).
  • Link  NICE TA197: Atrial fibrillation - dronedarone
    02.03.02  Expand sub section  Supraventricular and ventricular arrhythmias
    02.03.02  Expand sub section  Ventricular arrhythmias
    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Track Changes
    Display tracking information
    click to search
    Link to adult BNF
    click to search
    Link to children's BNF
    click to search
    Link to SPCs
    Scottish Medicines Consortium
    Cytotoxic Drug
    Cytotoxic Drug
    Controlled Drug
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHS England

    Traffic Light Status Information

    Status Description


    Medicines suitable to be prescribed in primary care after Specialist* recommendation or initiation. A supporting prescribing guideline may be requested which must have been agreed by the relevant secondary care trust D&TC(s). *Specialist is defined as a clinician who has undertaken an appropriate formal qualification or recognised training programme within the described area of practice.   

    Amber 1

    Medicines that should be initiated by a specialist and prescribed by primary care prescribers only under a shared care protocol, once the patient has been stabilised. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s) (D&TC) * All drugs awaiting the production or approval of a shared care guideline default to RED   

    Cancer Drug Fund

    Cancer Drug Fund   


    Medicines suitable for routine use and can be prescribed within primary care within their licensed indication, in accordance with nationally recognised formularies, for example the BNF, BNF for Children, Medicines for Children or Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing.  

    Green Specialist Initiation

    These drugs should be initiated only by a hospital or specialist clinician (GPSi) but there is no requirement for additional monitoring over the general requirements for all medicines. Some may require short or medium specialist monitoring of efficacy or dose titration before transferring in Primary care. The GP should have all the information they require to support continued prescribing.   

    Green Specialist Recomendation



    Grey - Medicines, which the Drug & therapeutics Committee has actively reviewed and does not recommend for use at present following a review of clinical and/or cost effective data. Grey (assessment in progress) - will be reviewed at a future D&T meeting. Grey (awaiting submission) - The D&T are awaiting a submission from an appropriate practitioner. If you wish to make a submission for this medicine to be added to the formulary please email .   

    Non Formulary

    Not recommended for prescribing as initial therapy, but can be continued if patient already stable on treatment   


    Medicines which should normally be prescribed by specialists only. ** For patients already receiving prescriptions in primary care - continue. No new patients to receive prescriptions in primary care   


    Unlicensed Medication